Experienced in Acute Myeloid Leukemia (AML)

Dr. Shelton A. Viola

Pediatrics | Hematology | Oncology
620 John Paul Jones Cir, 
Portsmouth, VA 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Offers Telehealth
Experienced in Acute Myeloid Leukemia (AML)
620 John Paul Jones Cir, 
Portsmouth, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Shelton Viola is a Pediatrics specialist and a Hematologist in Portsmouth, Virginia. Dr. Viola is rated as an Experienced provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). His top areas of expertise are Leukemia, Ganglioneuroblastoma, Acute Myeloid Leukemia (AML), and Neuroblastoma. Dr. Viola is currently accepting new patients.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 1 clinical trial in the study of Acute Myeloid Leukemia (AML).

Specialties
Pediatrics
Hematology
Oncology
Licenses
Pediatric Hematology-Oncology in TN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

620 John Paul Jones Cir, Portsmouth, VA 23708
Other Locations
262 Danny Thomas Pl, Memphis, TN 38105

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: September 18, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: August 12, 2025
Intervention Type: Other
Neuroblastoma Biology Studies
Neuroblastoma Biology Studies
Enrollment Status: Recruiting
Publish Date: April 16, 2025
Intervention Type: Other
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug, Radiation
Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib
Study Phase: Phase 2
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Temsirolimus, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine
Study Phase: Phase 3
Renal Tumors Classification, Biology, and Banking Study
Renal Tumors Classification, Biology, and Banking Study
Enrollment Status: Active_not_recruiting
Publish Date: March 25, 2025
Intervention Type: Other
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
Enrollment Status: Completed
Publish Date: April 30, 2024
Intervention Type: Drug
Study Drugs: Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate
Study Phase: Phase 2
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: October 03, 2023
Intervention Type: Other
View 11 Less Clinical Trials

4 Total Publications

Affirming Hormone Treatment for a Transgender Adolescent After a Venous Thromboembolic Event.
Affirming Hormone Treatment for a Transgender Adolescent After a Venous Thromboembolic Event.
Journal: Journal of pediatric hematology/oncology
Published: July 18, 2021
Similar Doctors
Distinguished in Acute Myeloid Leukemia (AML)
Dr. Gary L. Simmons
Hematology Oncology | Hematology | Oncology
Distinguished in Acute Myeloid Leukemia (AML)
Dr. Gary L. Simmons
Hematology Oncology | Hematology | Oncology

Virginia Oncology Associates

6251 E Virginia Beach Blvd, Suite 200, 
Norfolk, VA 
 (6.3 miles away)
757-466-8683
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gary Simmons is a Hematologist Oncology specialist and a Hematologist in Norfolk, Virginia. Dr. Simmons is rated as a Distinguished provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). His top areas of expertise are Multiple Myeloma, Non-Hodgkin Lymphoma, Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Simmons is currently accepting new patients.

Distinguished in Acute Myeloid Leukemia (AML)
Dr. Darla Liles
Hematology
Distinguished in Acute Myeloid Leukemia (AML)
Dr. Darla Liles
Hematology

Vidant Medical Group LLC

211 Virginia Rd, 
Edenton, NC 
 (56.1 miles away)
252-482-6219
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Darla Liles is a Hematologist in Edenton, North Carolina. Dr. Liles is rated as a Distinguished provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Autoimmune Hemolytic Anemia, Bone Marrow Aspiration, and Fasciotomy.

Advanced in Acute Myeloid Leukemia (AML)
Dr. John F. Miller
Hematology Oncology | Hematology | Oncology
Advanced in Acute Myeloid Leukemia (AML)
Dr. John F. Miller
Hematology Oncology | Hematology | Oncology

Peninsula Cancer Institute, LLC

120 Kings Way, Suite 3100, 
Williamsburg, VA 
 (37.2 miles away)
757-345-5724
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Miller is a Hematologist Oncology specialist and a Hematologist in Williamsburg, Virginia. Dr. Miller is rated as a Distinguished provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). His top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Paget Disease of the Breast, Large-Cell Immunoblastic Lymphoma, and Chronic Lymphocytic Leukemia (CLL). Dr. Miller is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Viola's expertise for a condition
ConditionClose
        View All 8 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile